Angion Biomedica Corp
Angion Biomedica Corp logo
ANGN

Angion Biomedica Corp (ANGN)

$0.9212.2%

Market is closed
– opens on 8 PM, 05 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$0.86
Day's Range
$0.92
$0.78
52-Week Range
$3.71
1 month return2.8%
3 month return9.8%
1 year return73.1%
5 year return94.59%

Company Information

Angion Biomedica Corp. is committed to transforming the treatment paradigm for patients suffering from acute organ injuries and fibrotic diseases for which there are no approved medicines or where existing approved medicines have limitations. Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic currently being evaluating in a Phase 3 registration trial for delayed graft function in patients undergoing deceased donor kidney transplantation, a Phase 2 trial in cardiac-surgery associated acute kidney injury, and a Phase 2 trial in patients with COVID-19 related pneumonia at high risk for acute respiratory distress syndrome. Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1. Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor.
OrganizationAngion Biomedica Corp
Employees71
CEODr. Jay R. Venkatesan M.B.A., M.D., Ph.D.
IndustryHealthcare

Analyst Recommendation

based on 4 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 4 Wall street analysts offering stock ratings for Angion Biomedica Corp(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 63.04%

Current

$0.92

Target

$1.5

Recommendation Trend

Based on 4 analyst

Current1M Ago3M Ago
Buy
4
0
6
Hold
0
5
4
Sell
0
3
0
Consensus
BUY
HOLD
BUY

Highlights

Market Capitalization
24.7M
Book Value
$1.67
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.07
Wall Street Target Price
1.5

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
0.54
Enterprise Value
-24084668
Enterprise Value/Revenue
2.26
Enterprise Value/Ebitda
2.2

Technicals

50 Day MA
0.94
200 Day MA
1.36

Institutional Holdings

Nantahala Capital Management, LLC

3.76%

Bvf Inc

3.56%

Vanguard Group Inc

2.14%

CM Management, LLC

1.99%

LAKE STREET ADVISORS GROUP, LLC

0.82%

Renaissance Technologies Corp

0.71%

Discover more

Frequently Asked Questions

What is Angion Biomedica Corp share price today?

Can Indians buy Angion Biomedica Corp shares?

How can I buy Angion Biomedica Corp shares from India?

Can Fractional shares of Angion Biomedica Corp be purchased?

What are the documents required to start investing in Angion Biomedica Corp stocks?

What are today’s High and Low prices of Angion Biomedica Corp?

What are today’s traded volumes of Angion Biomedica Corp?

What is today’s market capitalisation of Angion Biomedica Corp?

What is the 52 Week High and Low Range of Angion Biomedica Corp?

How much percentage Angion Biomedica Corp is down from its 52 Week High?

How much percentage Angion Biomedica Corp is up from its 52 Week low?

What are the historical returns of Angion Biomedica Corp?

Who is the Chief Executive Officer (CEO) of Angion Biomedica Corp?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*